Publication | Closed Access

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

MedicineImmunologyPathologyImmune Checkpoint InhibitorNeutrophil-to-lymphocyte RatioPlatelet-to-lymphocyte RatioCancer TreatmentOncologyRadiation OncologyLung CancerPrognostic Markers